DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy
dc.contributor.author | Graf, Franziska | |
dc.contributor.author | Fahrer, Jörg | |
dc.contributor.author | Maus, Stephan | |
dc.contributor.author | Morgenstern, Alfred | |
dc.contributor.author | Bruchertseifer, Frank | |
dc.contributor.author | Venkatachalam, Senthil | |
dc.contributor.author | Fottner, Christian | |
dc.contributor.author | Weber, Matthias M. | |
dc.contributor.author | Huelsenbeck, Johannes | |
dc.contributor.author | Schreckenberger, Mathias | |
dc.contributor.author | Kaina, Bernd | |
dc.contributor.author | Miederer, Matthias | |
dc.date.accessioned | 2022-10-13T09:21:22Z | |
dc.date.available | 2022-10-13T09:21:22Z | |
dc.date.issued | 2014 | |
dc.description.abstract | Rationale Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to the beta-particle emitter Lutetium-177 labeled somatostatin-analogue DOTATOC in vitro and in vivo were studied to evaluate the significance of γH2AX-foci formation. Methods To determine the relative biological effectiveness (RBE) between the two isotopes (as - biological consequence of different ionisation-densities along a particle-track), somatostatin expressing AR42J cells were incubated with Ac-225-DOTATOC and Lu-177-DOTATOC up to 48 h and viability was analyzed using the MTT assay. DNA double strand breaks (DSB) were quantified by immunofluorescence staining of γH2AX-foci. Cell cycle was analyzed by flow cytometry. In vivo uptake of both radiolabeled somatostatin-analogues into subcutaneously growing AR42J tumors and the number of cells displaying γH2AX-foci were measured. Therapeutic efficacy was assayed by monitoring tumor growth after treatment with activities estimated from in vitro cytotoxicity. Results Ac-225-DOTATOC resulted in ED50 values of 14 kBq/ml after 48 h, whereas Lu-177-DOTATOC displayed ED50 values of 10 MBq/ml. The number of DSB grew with increasing concentration of Ac-225-DOTATOC and similarly with Lu-177-DOTATOC when applying a factor of 700-fold higher activity compared to Ac-225. Already 24 h after incubation with 2.5–10 kBq/ml, Ac-225-DOTATOC cell-cycle studies showed up to a 60% increase in the percentage of tumor cells in G2/M phase. After 72 h an apoptotic subG1 peak was also detectable. Tumor uptake for both radio peptides at 48 h was identical (7.5%ID/g), though the overall number of cells with γH2AX-foci was higher in tumors treated with 48 kBq Ac-225-DOTATOC compared to tumors treated with 30 MBq Lu-177-DOTATOC (35% vs. 21%). Tumors with a volume of 0.34 ml reached delayed exponential tumor growth after 25 days (44 kBq Ac-225-DOTATOC) and after 21 days (34 MBq Lu-177-DOTATOC). Conclusion γH2AX-foci formation, triggered by beta- and alpha-irradiation, is an early key parameter in predicting response to internal radiotherapy. | en_GB |
dc.description.sponsorship | DFG, Open Access-Publizieren Universität Mainz / Universitätsmedizin | de |
dc.identifier.doi | http://doi.org/10.25358/openscience-7977 | |
dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/7992 | |
dc.language.iso | eng | de |
dc.rights | CC-BY-4.0 | * |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.ddc | 610 Medizin | de_DE |
dc.subject.ddc | 610 Medical sciences | en_GB |
dc.title | DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy | en_GB |
dc.type | Zeitschriftenaufsatz | de |
jgu.identifier.pmid | 24516620 | |
jgu.journal.issue | 2 | de |
jgu.journal.title | PLoS one | de |
jgu.journal.volume | 9 | de |
jgu.organisation.department | FB 04 Medizin | de |
jgu.organisation.name | Johannes Gutenberg-Universität Mainz | |
jgu.organisation.number | 2700 | |
jgu.organisation.place | Mainz | |
jgu.organisation.ror | https://ror.org/023b0x485 | |
jgu.pages.alternative | e88239 | de |
jgu.publisher.doi | 10.1371/journal.pone.0088239 | de |
jgu.publisher.issn | 1932-6203 | de |
jgu.publisher.name | PLoS | de |
jgu.publisher.place | Lawrence, Kan. | de |
jgu.publisher.uri | http://dx.doi.org/10.1371/journal.pone.0088239 | de |
jgu.publisher.year | 2014 | |
jgu.rights.accessrights | openAccess | |
jgu.subject.ddccode | 610 | de |
jgu.type.dinitype | Article | en_GB |
jgu.type.resource | Text | de |
jgu.type.version | Published version | de |
opus.affiliated | Fahrer, Jörg | |
opus.affiliated | Fottner, Christian | |
opus.affiliated | Weber, Matthias M. | |
opus.affiliated | Schreckenberger, Mathias | |
opus.affiliated | Kaina, Bernd | |
opus.affiliated | Miederer, Matthias | |
opus.date.modified | 2018-08-08T08:15:15Z | |
opus.identifier.opusid | 27325 | |
opus.importsource | pubmed | |
opus.institute.number | 0414 | |
opus.institute.number | 0422 | |
opus.institute.number | 0425 | |
opus.metadataonly | false | |
opus.organisation.string | FB 04: Medizin: Institut für Toxikologie | de_DE |
opus.organisation.string | FB 04: Medizin: Klinik und Poliklinik für Nuklearmedizin | de_DE |
opus.organisation.string | FB 04: Medizin: I. Medizinische Klinik und Poliklinik | de_DE |
opus.subject.dfgcode | 00-000 | |
opus.type.contenttype | Keine | de_DE |
opus.type.contenttype | None | en_EN |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- dna_double_strand_breaks_as_p-20220925155731505.pdf
- Size:
- 3.22 MB
- Format:
- Adobe Portable Document Format
- Description: